161 related articles for article (PubMed ID: 37842857)
21. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
22. A new targeted treatment for patients with a germline
Verdaguer H; Acosta D; Macarulla T
Future Oncol; 2020 Nov; 16(33):2691-2700. PubMed ID: 32799562
[TBL] [Abstract][Full Text] [Related]
23. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
24. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
[TBL] [Abstract][Full Text] [Related]
25. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
26. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
27. Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer.
Lynce F; Robson M
Cancer Treat Res; 2023; 186():91-102. PubMed ID: 37978132
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
29. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Zhu H; Wei M; Xu J; Hua J; Liang C; Meng Q; Zhang Y; Liu J; Zhang B; Yu X; Shi S
Mol Cancer; 2020 Mar; 19(1):49. PubMed ID: 32122376
[TBL] [Abstract][Full Text] [Related]
31. Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.
Thein KZ; Thawani R; Kummar S
Cancer Treat Res; 2023; 186():143-170. PubMed ID: 37978135
[TBL] [Abstract][Full Text] [Related]
32. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
33.
Rosen MN; Goodwin RA; Vickers MM
World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
[TBL] [Abstract][Full Text] [Related]
34. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage.
Piao L; Nakagawa H; Ueda K; Chung S; Kashiwaya K; Eguchi H; Ohigashi H; Ishikawa O; Daigo Y; Matsuda K; Nakamura Y
Genes Chromosomes Cancer; 2011 Jan; 50(1):13-24. PubMed ID: 20931645
[TBL] [Abstract][Full Text] [Related]
35. Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors.
Golan T; Raitses-Gurevich M; Beller T; Carroll J; Brody JR
Cancer Treat Res; 2023; 186():125-142. PubMed ID: 37978134
[TBL] [Abstract][Full Text] [Related]
36. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
38. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
[No Abstract] [Full Text] [Related]
39. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials.
Kamel D; Gray C; Walia JS; Kumar V
Curr Drug Targets; 2018; 19(1):21-37. PubMed ID: 28699513
[TBL] [Abstract][Full Text] [Related]
40. New agents for the management of resistant metastatic breast cancer.
Anampa J; Sparano JA
Expert Opin Pharmacother; 2017 Dec; 18(17):1815-1831. PubMed ID: 29171761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
